Industry
Biotechnology
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Loading...
Open
6.56
Mkt cap
1.8B
Volume
1.8M
High
6.61
P/E Ratio
81.75
52-wk high
7.63
Low
6.46
Div yield
N/A
52-wk low
3.17
Portfolio Pulse from
November 08, 2024 | 1:45 am
Portfolio Pulse from
November 08, 2024 | 12:00 am
Portfolio Pulse from
November 05, 2024 | 9:30 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 10:04 am
Portfolio Pulse from Benzinga Insights
September 23, 2024 | 5:35 pm
Portfolio Pulse from Benzinga Newsdesk
September 18, 2024 | 10:17 am
Portfolio Pulse from Benzinga Newsdesk
August 28, 2024 | 4:46 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.